Back

Featured Topics

Behind The Science
Breast Cancer
Cancer Immunotherapy
Hematology
Lung Cancer
Manufacturing
Multiple Sclerosis
Oncology
Ophthalmology
Partnering
Respiratory Health
Rheumatology
About Us Contact Us Leadership Awards & Recognition Investors Suppliers Compliance
  • Twitter
  • Facebook
  • LinkedIn

The Immune System in Multiple Sclerosis


Read More Stories
Apr 25, 2017

BREAKING THE RULES:

The Immune System in Multiple Sclerosis (MS)

Our immune system usually defends and protects the body from invaders. In people with MS, a disease of the central nervous system, the body’s immune system mistakenly attacks the insulation around nerve cells (myelin) in the brain, spinal cord and optic nerves.

The Immune Cell team in MS

MACROPHAGE

MICROGLIA

NATURAL KILLER CELL

T CELL

B CELL

A LEAKY BARRIER

Most types of immune cells aren't normally found in the nervous system because of the barrier that protects the brain from potentially harmful elements circulating in the blood.

In people with MS, this barrier is compromised – allowing T and B cells to move into the brain and spinal cord.2,3

T cells have long been believed to lead the attack on the nervous system. Scientists now believe that B cells also play an important role in MS.4

THE B CELL LINEUP5

There are different types of B cells, depending on their stage of development. Each type of B cell has a job to do - from recognizing foreign invaders to making antibodies.

STEM
CELL
PRO
B CELL
PRE
B CELL
IMMATURE
B CELL
ACTIVATED B CELL
MEMORY
B CELL
PLASMA
CELL

B cells can be distinguished by different combinations of PROTEINS on their surface. Here are a few examples:

CD19
CD20
CD27

4 MOVES T AND B CELLS MAY MAKE IN MS

B cells recognize MYELIN and tell T cells to launch an IMMUNE ATTACK6,7

T and B cells release chemicals that attract other immune cells that cause INFLAMMATION8,9

B cells make and release ANTIBODIES that attack myelin and recruit the help of other immune cells10,11

T and B cells may establish permanent residence in the central NERVOUS SYSTEM and continue the attack12,13

References: 1 Duffy SS, et al. (2014). The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis. Mult Scler Int, 2014:285245. 2 Ortiz GG, et al. (2014). Role of the blood-brain barrier in multiple sclerosis. Archives of Medical Research, 45:687-697. 3 Larochelle C. (2011) How do immune cells overcome the blood–brain barrier in multiple sclerosis? FEBS Letters, 585(23):3770-3780. 4 Cross AH, Waubant E. (2011). MS and the B cell controversy. Biochim Biophys Acta, 1812(2):231-238. 5 Dalakas MC. (2008). B cells as therapeutic targets in autoimmune neurological disorders. Nature Clinical Practice Neurology, 4(10):557-567. 6 Constant SL. (1999). B lymphocytes as antigen-presenting cells for CD4+ T cell priming in vivo. J Immunol, 162(10):5695-5703. 7 Crawford A, et al. (2006). Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol, 176(6):3498-3506. 8 Bar-Or A, et al. (2010). Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol, 67(4):452-461. 9 Duddy M, et al. (2007). Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol, 178(10):6092-6099. 10 Genain CP, et al. (1999). Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med, 5(2):170-175. 11 Storch MK, et al. (1998). Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol, 43(4):465-471. 12 Serafini B, et al. (2004). Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol, 14(2):164-174. 13 Magliozzi R, et al. (2010). A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol, 68(4):477-493.

www.gene.com
© 2015 Genentech USA, Inc. All rights reserved.
OCR/030217/0028


Tags:

  • Multiple Sclerosis

Read More Stories

Read about breakthrough science, the everyday people who make it happen, and the patients we serve.

  • Now Hiring
  • Find A Job
  • Professional Areas
  • Diversity & Inclusion
  • Chief Diversity Officer
  • Fostering Belonging
  • Health Equity
  • Advancing Inclusive Research
  • Transforming Society
  • Our 2021 Diversity & Inclusion Report
  • Our Work in Action
  • Kindergarten to Careers
  • For Scientists
  • Our Scientists
  • Publications
  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
  • For Patients
  • Our Medicines
  • Financial Support
  • Genentech Patient Foundation
  • Understanding Insurance
  • Medicine Information Support
  • Clinical Trial Information
  • Advancing Inclusive Research
  • Our Approach to Pricing
  • Patient Advocacy
  • Create With Us
  • Disease Education
  • For Medical Professionals
  • Our Medicines & Products
  • Our Pipeline
  • Medical Resources
  • Clinical Trial Information
  • Sunshine Act Compliance
  • Product Security
  • For Partners
  • Our Approach
  • What We Are Looking For
  • Partner With Us
  • Our Stories
  • For Media
  • News Features
  • Press Releases
  • Statements
  • Company Information
  • Sign Up For News Alerts
  • For Good
  • Giving
  • Diversity & Inclusion
  • Sustainability
  • About Us
  • Leadership
  • Policy & Advocacy
  • Our Focus on Oncology
  • Awards & Recognition
  • Investors
  • Suppliers
  • Our Approach to Pricing
  • CA Transparency in Supply
  • Compliance Overview
  • Contact Us
  • Call Us
  • Email Us
  • Visit us
  • Submit a Medical Inquiry
  • Submit a Media Inquiry
  • —
  • Privacy Policy
  • Terms & Conditions
  • Accessibility
© 2023 Genentech, Inc. All rights reserved. This site is intended for US residents only.